Galactagogues for Low Milk Supply: Domperidone, Metoclopramide & Safety
Understanding Low Milk Supply: A Common Concern for Indian Mothers
Perceived insufficient milk supply is the most commonly cited reason for early cessation of exclusive breastfeeding in India, reported by 35-55% of mothers who discontinue breastfeeding before six months. However, true physiological insufficient lactation (primary lactation failure) affects only 2-5% of women. The vast majority of cases involve modifiable factors such as poor latch technique, infrequent feeding, supplementation with formula that reduces breast stimulation, maternal stress, or medical conditions affecting prolactin signalling.
When non-pharmacological interventions prove insufficient, galactagogues, medications and substances that increase breast milk production, become an important therapeutic option. In India, domperidone and metoclopramide are the two most widely prescribed pharmaceutical galactagogues, while herbal options like fenugreek (methi), shatavari, and fennel have deep roots in Ayurvedic and traditional practice.
This guide provides a comprehensive, evidence-based assessment of galactagogues available in India, incorporating Hale's Lactation Risk Categories, Relative Infant Dose (RID) data, IAP breastfeeding guidelines, and practical prescribing recommendations for clinicians and mothers.
The Physiology of Milk Production and Prolactin
Understanding how galactagogues work requires knowledge of the hormonal regulation of lactation:
- Prolactin: The primary lactogenic hormone secreted by the anterior pituitary. Prolactin levels rise during pregnancy and remain elevated during breastfeeding in response to nipple stimulation. Prolactin stimulates alveolar epithelial cells in the breast to synthesize and secrete milk.
- Dopamine inhibition: Prolactin secretion is tonically inhibited by dopamine from the hypothalamic tuberoinfundibular pathway acting on D2 receptors on lactotrophs. Blocking this dopamine inhibition raises prolactin levels.
- Feedback mechanism: Milk removal triggers the prolactin reflex via afferent neural signals from the nipple, creating a supply-demand loop. Incomplete milk removal reduces prolactin stimulation, decreasing supply.
- Oxytocin: The milk ejection (let-down) reflex is mediated by oxytocin, which causes myoepithelial cells to contract and eject milk from the alveoli into the ducts.
Galactagogues primarily work by blocking dopamine D2 receptors in the pituitary, thereby removing the tonic inhibition of prolactin and allowing prolactin levels to rise. This mechanism explains why dopamine antagonists like domperidone and metoclopramide are effective galactagogues.
Domperidone: The Preferred Pharmaceutical Galactagogue
Pharmacological Profile
| Parameter | Domperidone |
|---|---|
| Drug class | Peripheral dopamine D2 antagonist |
| Hale's category | L1 (Safest) |
| RID | 0.01-0.04% |
| M/P ratio | 0.25 |
| Oral bioavailability | 13-17% |
| Half-life | 7.5 hours |
| Blood-brain barrier crossing | Minimal (peripheral action) |
| Prolactin increase | 2-3 fold elevation |
| Milk volume increase | 30-60% in most studies |
Dosing for Galactagogue Use
- Starting dose: 10 mg orally three times daily (30 mg/day), taken 30 minutes before meals.
- Dose escalation: If response is inadequate after 3-5 days, may increase to 20 mg three times daily (60 mg/day). Some specialists use up to 20 mg four times daily (80 mg/day) for NICU mothers pumping for preterm infants.
- Duration: Typical course is 2-4 weeks. Response is usually seen within 3-5 days.
- Tapering: Gradual dose reduction over 1-2 weeks prevents rebound milk supply decrease. Reduce by 10 mg every 3-5 days.
Safety and Side Effects
- Maternal side effects: Generally well tolerated. Dry mouth, headache, and abdominal cramps occur in less than 7% of women. No significant CNS effects due to poor blood-brain barrier penetration.
- QT prolongation concern: High-dose domperidone (above 60 mg/day) has been associated with rare cardiac arrhythmias. The European Medicines Agency (EMA) restricted domperidone doses to 30 mg/day for gastrointestinal indications, but lactation specialists note that the risk-benefit profile at galactagogue doses remains favourable in young, otherwise healthy postpartum women.
- Infant safety: With an RID of only 0.01-0.04%, the amount of domperidone reaching the infant through breast milk is pharmacologically insignificant. No adverse neonatal effects have been reported in clinical studies.
Metoclopramide: An Alternative with More Side Effects
Pharmacological Profile
| Parameter | Metoclopramide |
|---|---|
| Drug class | Central and peripheral dopamine D2 antagonist |
| Hale's category | L2 (Safer) |
| RID | 4.7-14.3% |
| M/P ratio | 0.5-4.06 |
| Oral bioavailability | 65-95% |
| Half-life | 5-6 hours |
| Blood-brain barrier crossing | Significant (central action) |
| Prolactin increase | 2-3 fold elevation |
| Milk volume increase | 25-100% (variable) |
Why Metoclopramide Is Less Preferred
- CNS side effects: Because metoclopramide readily crosses the blood-brain barrier, up to 30% of women experience depression, anxiety, drowsiness, fatigue, restlessness, or akathisia (inability to sit still).
- Extrapyramidal symptoms: Acute dystonia, tardive dyskinesia, and drug-induced parkinsonism are reported, particularly with prolonged use.
- FDA black box warning: Tardive dyskinesia risk with use exceeding 12 weeks. This is particularly concerning for postpartum women who may already be vulnerable to mood disorders.
- Higher RID: At 4.7-14.3%, the RID is considerably higher than domperidone, though still generally acceptable for term infants.
Metoclopramide remains widely used in India due to its low cost (INR 2-5 per tablet) and universal availability, but domperidone should be preferred when accessible.
Comparative Efficacy: Domperidone vs Metoclopramide
| Parameter | Domperidone | Metoclopramide |
|---|---|---|
| Prolactin elevation | 2-3 fold | 2-3 fold |
| Milk volume increase | 30-60% | 25-100% |
| Time to effect | 3-5 days | 2-5 days |
| Maternal depression risk | Not increased | Significantly increased |
| Extrapyramidal risk | Negligible | 5-10% |
| QT prolongation | Rare (dose-dependent) | Rare |
| Infant side effects | None reported | Rare intestinal discomfort |
| Cost (India) | INR 3-8 per tablet | INR 2-5 per tablet |
| Hale's category | L1 | L2 |
Herbal Galactagogues in Indian Practice
India has a rich tradition of herbal galactagogues rooted in Ayurveda and folk medicine. While clinical evidence is limited compared to pharmaceutical options, these are widely used and deserving of balanced assessment:
Fenugreek (Trigonella foenum-graecum / Methi)
- Traditional use: One of the most commonly used herbal galactagogues worldwide. Methi seeds and leaves are dietary staples in India.
- Evidence: A 2018 systematic review found modest evidence supporting milk supply increase, though study quality was generally low.
- Dose: Typically 2-3 capsules (580-610 mg each) three times daily, or fenugreek tea 3 cups daily.
- Side effects: Maple syrup odour in urine, sweat, and breast milk; possible hypoglycaemia; allergic reactions in women allergic to peanuts or chickpeas (same legume family); diarrhoea at high doses.
- Hale's category: L3 (limited data).
Shatavari (Asparagus racemosus)
- Traditional use: A cornerstone of Ayurvedic postpartum care. The name literally means "she who possesses a hundred husbands," reflecting its association with female reproductive health.
- Evidence: Animal studies show prolactin-elevating and milk-yield-increasing effects. Human clinical trial data is sparse but a few Indian studies suggest benefit.
- Dose: Varies widely; typically 500-1000 mg twice daily as capsules or as traditional preparations.
- Side effects: Generally well tolerated; may cause allergic reactions in asparagus-sensitive individuals.
Non-Pharmacological Strategies: The First Line of Treatment
Before prescribing any galactagogue, IAP guidelines mandate addressing modifiable causes of low milk supply:
- Optimise latch and positioning: A certified lactation consultant should assess latch. Poor latch is the most common correctable cause of low supply in India.
- Increase feeding frequency: Feed on demand, at least 8-12 times in 24 hours. Both breasts should be offered at each feed.
- Add pumping sessions: Pumping after breastfeeds or between feeds provides additional prolactin stimulation.
- Skin-to-skin contact: Kangaroo mother care stimulates oxytocin and prolactin release.
- Address maternal health: Hypothyroidism, retained placental fragments, Sheehan syndrome, and PCOS can all impair lactation. Screen and treat as needed.
- Nutrition and hydration: Ensure adequate caloric intake (approximately 500 extra calories per day) and fluid intake.
- Stress reduction: Cortisol inhibits oxytocin release. Support from family and healthcare providers is essential.
For mothers of neonates requiring NICU stay or phototherapy for jaundice, maintaining milk supply through pumping is crucial. HEAMAC neonatal care resources emphasize the importance of expressed breast milk for hospitalised newborns and provide support for establishing lactation during the NICU period.
Special Populations: Galactagogues for NICU Mothers
Mothers of preterm or sick neonates face unique challenges in establishing milk supply, as they must rely on breast pumping rather than direct breastfeeding during the initial NICU stay. These mothers benefit most from galactagogue therapy:
- Domperidone 10-20 mg three times daily started within the first 2 weeks postpartum has been shown to increase expressed breast milk volume by 44-96% in NICU mothers.
- The Academy of Breastfeeding Medicine (ABM) Protocol #9 supports domperidone use in mothers pumping for hospitalized infants.
- For premature infants, breast milk provides critical immunological protection and reduces the risk of necrotizing enterocolitis, making supply optimisation a medical priority.
Clinical Tip: When prescribing galactagogues, always combine with a structured pumping schedule: pump every 2-3 hours for 15-20 minutes per session, including at least once during the night. The pharmacological effect of the galactagogue is amplified when coupled with regular breast stimulation.
When to Stop Galactagogues: Tapering and Duration
Galactagogues should not be used indefinitely. The recommended approach involves defined treatment duration followed by gradual tapering to assess whether milk supply can be maintained independently through breast stimulation alone. For domperidone, a typical course of 2-4 weeks is recommended, followed by tapering by 10 mg every 3-5 days. Abrupt discontinuation can cause a sudden drop in prolactin levels and a rebound reduction in milk supply, which may be difficult to recover. Metoclopramide should ideally be limited to 2-3 weeks maximum to minimise the risk of tardive dyskinesia and other extrapyramidal effects.
Conclusion: Evidence-Based Approach to Low Milk Supply
Low breast milk supply is a common and often correctable condition. Non-pharmacological interventions addressing latch, feeding frequency, pumping, and maternal health should always be the first approach. When pharmaceutical galactagogues are needed, domperidone is the preferred agent due to its Hale's L1 rating, minimal RID of 0.01-0.04%, and favourable CNS safety profile compared to metoclopramide. Herbal galactagogues such as fenugreek and shatavari have cultural relevance in India but lack robust clinical evidence. Indian clinicians should follow IAP breastfeeding guidelines, prescribe evidence-based galactagogues at appropriate doses with defined treatment duration, and ensure ongoing lactation support to maximise breastfeeding success.